Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including stroke and myocardial infarction) in patients with a history of myocardial infarction (MI).
* In combination with aspirin, for the treatment of acute coronary syndrome (ACS).
## Adult Dosing
* **Post-MI (patients with a history of MI):** 90 mg orally twice daily for at least 12 months, followed by 60 mg orally twice daily.
* **Acute Coronary Syndrome (ACS):** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily. Treatment duration is typically 12 months.
* **Switching from clopidogrel or prasugrel:** No initial loading dose is required when switching to ticagrelor.
* **Switching to clopidogrel or prasugrel:** Consult specific guidelines; a loading dose of the alternative agent may be recommended.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients due to a lack of data.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required in patients with mild to moderate renal impairment. Use with caution in severe renal impairment.
## Contraindications
* Known hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
## Adverse Effects
* **Common:** Dyspnea, bleeding (major and minor), bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses, angioedema.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase ticagrelor concentrations. Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor concentrations.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4 and increase the concentration of concomitant CYP3A4 substrates (e.g., simvastatin, lovastatin). Max dose of simvastatin/lovastatin is 40 mg once daily.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor heart rate for bradycardia.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel and prasugrel which are irreversible.
* Dyspnea is a common side effect and does not always indicate underlying cardiac or pulmonary disease.
* Discontinuation of ticagrelor increases the risk of thrombotic events. Avoid premature discontinuation.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.
